


ajanta pharma limited

Regd. Office: 'Ajanta House', Charkop, Kandivli (W), Mumbai-67

Statement of Standalone Unaudited Financial Results for the quarter ended 30 June 2013

Particulars	₹ in Crores			
	3 months ended			Year Ended
	30/06/2013	31/03/2013	30/06/2012	31/03/2013
	Unaudited	Audited	Unaudited	Audited
1 Income from Operations				
(a) Net Sales (Net of excise duty)	215.39	249.21	170.81	828.50
(b) Other operating income	3.55	0.23	3.24	10.70
Total Income from Operations (net)	218.94	249.44	174.05	839.20
2 Expenditure				
(a) Cost of materials consumed	50.83	99.36	44.38	284.09
(b) Purchases of stock-in-trade	7.59	7.46	5.28	27.35
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	16.14	(17.46)	15.48	(11.41)
(d) Employee benefits expense	33.85	34.52	25.63	115.40
(e) Depreciation and amortisation expense	8.60	8.98	7.78	32.70
(f) Exchange rate difference (Net)	-	0.64	1.27	2.90
(g) Other expenses	59.44	56.49	46.19	213.59
Total expenses	176.45	189.99	146.01	664.62
3 Profit from operations before other income, finance costs & tax (1-2)	42.49	59.45	28.04	174.58
4 (a) Other Income	4.81	6.28	0.29	7.41
(b) Exchange rate difference (Net)	2.05	-	-	-
5 Profit from ordinary activities before finance costs & tax (3+4)	49.35	65.73	28.33	181.99
6 Finance costs	1.63	5.35	5.21	18.48
7 Profit from ordinary activities before tax (5-6)	47.72	60.38	23.12	163.51
8 Tax Expense	15.18	33.29	3.54	62.39
9 Net Profit for the period (7-8)	32.54	27.09	19.58	101.12
10 Paid-up Equity Share Capital	11.81	11.80	11.80	11.80
Face value of Equity Share - in ₹	5	5	10	5
11 Reserve excluding Revaluation Reserves	NA	NA	NA	344.48
12 Earnings Per Share - not annualised (refer note 4)				
(a) Basic - in ₹	13.89	11.56	8.36	43.17
(b) Diluted - in ₹	13.86	11.53	8.34	43.07
A PARTICULARS OF SHAREHOLDING				
1 Public Shareholding				
- Number of shares	6,219,064	6,321,498	3,297,120	6,321,498
- Percentage of shareholding	26.54%	27.00%	28.16%	27.00%
2 Promoters and promoter group shareholding				
a) Pledged/Encumbered				
- Number of shares	777,000	1,100,000	550,000	1,100,000
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	4.51%	6.43%	6.54%	6.43%
- Percentage of shares (as a % of the total share capital of the company)	3.32%	4.70%	4.70%	4.70%
b) Non-encumbered				
- Number of shares	16,437,736	15,995,502	7,861,380	15,995,502
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	95.49%	93.57%	93.46%	93.57%
- Percentage of shares (as a % of the total share capital of the company)	70.14%	68.30%	67.14%	68.30%
B INVESTOR COMPLAINTS				
				3 Months ended 30/06/2013
Pending at the beginning of the quarter and remaining unresolved at the end of the quarter				Nil
Received and disposed off during the quarter				17
Notes :				
1 Above results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 29 July 2013.				
2 Statutory Auditors have carried out Limited Review of the above results.				
3 Board of Directors have recommended Bonus Shares in the ratio of one new fully paid-up Equity Share for every two fully paid-up Equity Share.				
4 Earning per share has been disclosed considering increased number of shares post sub division, for all periods reported herein above.				
5 During the quarter, 16,800 equity shares of ₹5 each fully paid-up were allotted upon exercise of vested stock options pursuant to ESOS 2011, resulting in an increase in paid-up share capital by ₹0.01Cr and share premium by ₹0.25Cr.				
6 The company has one segment of activity namely, pharmaceuticals.				
7 Figures for the quarter ended 31 March 2013 are the balancing figures between audited figures for the financial year ended 31 March 2013 and the year to date limited review figures for the nine months period ended 31 December 2012.				
8 Previous period's figures have been regrouped wherever necessary.				
				By order of the Board For Ajanta Pharma Ltd.
				
				Yogesh M. Agrawal Managing Director
Mumbai, 29 July 2013				



Press Release

Ajanta Pharma begins the year with satisfactory performance

Mumbai - (July 29, 2013) - Ajanta Pharma Limited, a specialty focused pharmaceutical formulation company, has announced its results today where it continued its growth journey during the quarter ended June 30th 2013 with yet another satisfactory performance.

Highlights of Q1 FY14 standalone financial performance are

- Revenue from operations at Rs.219crs (Rs.174crs), growth of 26% over Q1 last year
- EBITDA at Rs.51crs (Rs.37crs), growth of 38% over same quarter last year
- Profit before Tax at Rs.48crs (Rs.23crs), growth of 106% over same quarter last year
- Profit after Tax at Rs.33crs (Rs.20crs), growth of 66% over same quarter last year
- Exports contributed 55% of the Net Sales for the quarter

Commenting on the results, Mr. Yogesh Agrawal, Managing Director said “Our sustained performance quarter after quarter reflects the result of our undivided commitment towards brand building leading to sustained business. We have been able to build a strong brand equity across geographies - India and overseas in the branded generic space”.

During the quarter, company filed 1 more ANDA with USFDA, taking the total tally to 15 ANDAs (2 approved and 13 waiting for approval). On the occasion of completing 40 years of ‘Serving Global Health Care Needs’, Company’s Board has recommended issue of bonus shares in the ratio of 1 share for every 2 shares held.

About Ajanta Pharma Limited

Ajanta Pharma is a speciality pharmaceutical formulation company. Ranked 45th in the Indian formulation market (IMS MAT Mar’13); company has leading brands in therapeutic segments of Ophthalmology, Dermatology and Cardiology. Many of company’s products are first in the market place and are leading in their sub therapeutic segments. Company has a well established branded generic business in emerging markets of Asia, Africa and Latin America. It has entered in the regulated markets of USA last year and is building a portfolio of ANDAs for this market. It has also received marketing authorization in 11 EU countries including UK, for one of its product.

For last 10 years, company’s consolidated performance has been outstanding with CAGR of 23% in revenue and 53% in net profit.

INVESTOR CONTACTS:

Deodatta Pandit, Company Secretary

+91 22 66061203 Email : deodatta.pandit@ajantapharma.com

Ajanta Pharma has its State of the Art R&D centre for formulation development, located at Mumbai, having a team of more than 250 people. Company has world class manufacturing facilities - 4 located in India and 1 at Mauritius. One of the manufacturing facilities in India holds approval from US FDA, UK MHRA, World health organisation (WHO) Pre-qualification, apart from having the approval from FDA of many other countries. Company is setting up two more manufacturing facilities in India, one for regulated markets and another for domestic and rest of the world markets. For more details please visit our website www.ajantapharma.com



Page 2 of 2

INVESTOR CONTACTS:

Deodatta Pandit, Company Secretary

+91 22 66061203 Email : deodatta.pandit@ajantapharma.com